Somerset, N.J. – July 20, 2017 — The Catalent Applied Drug Delivery Institute today announced that it has entered into a collaboration with the Department of Pharmacy Practice at Rutgers University, with a view to identify and address the specific challenges of pediatric formulation and drug delivery.

This collaboration will allow for research into the development and administration of medicines to children, including the prevalence of extemporaneous compounding of drug products for ease of administration to pediatric patients, and any safety and efficacy consequences. The goal of the collaboration is to identify therapies and diseases for which there is a high need for pediatric-friendly formulations, and to build awareness and advocate for targeted translational research to address the specific needs of this underserved patient group.

“Clinical experience has shown us that current pediatric drug formulations are often difficult to administer to children and increase the likelihood for a medication error when compared with adult formulations. There is a clear need for research in this area, to further elucidate the gaps in drug delivery for young children, and in order to improve therapeutic outcomes and the patient experience,” commented Dr. Rachel Meyers, Clinical Associate Professor in the Pharmacy Practice Department at the Ernest Mario School of Pharmacy, Rutgers University.

“This continues to expand the academically productive relationship that exists between Catalent and the Ernest Mario School of Pharmacy,” added Dr. Joseph Barone, Dean and Professor II at the Ernest Mario School of Pharmacy.

“Through this exciting partnership, we will examine and highlight the unmet scientific, clinical, and patient needs, and look to develop a suitable pediatric-specific drug formulation toolkit to address them,” added Dr. Cornell Stamoran, founder of the Catalent Applied Drug Delivery Institute and Catalent’s VP Strategy. “Most initiatives focus on individual new drugs or disease areas – we’re collaborating to identify a broad platform, founded on rigorous stakeholder insights, to establish a foundation for future pediatric drug development.

Established in 2012, the Catalent Applied Drug Delivery Institute seeks to accelerate the use of advanced formulations, dose forms and devices to enable improved treatments for patients. In June 2014, the Institute created the Non-Invasive Macromolecule Delivery Consortium as a number of working groups looking at alternative delivery routes to injection for biologics and other large molecule therapeutics.

About Catalent Applied Drug Delivery Institute

Catalent’s Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments, and foster industry collaboration on major issues pertaining to drug development, formulation, and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.

For more details on the Catalent Institute, visit and follow the Catalent Institute on Twitter: @DrugDeliveryIns

About Catalent

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. 

Catalent is headquartered in Somerset, New Jersey. For more information, visit

More products. Better treatments. Reliably supplied.™